Entrada Therapeutics Inc (TRDA) AI Stock Analysis

164 Followers

Entrada Therapeutics Inc

(NASDAQ:TRDA)

Select Model

Rating:47Neutral

Price Target:$5.00▲(2.25% Upside)

Action:reiterated

Date:11/05/26

The score is held down primarily by weak financial performance (renewed heavy losses, substantial ongoing cash burn, and declining equity). Technicals also remain bearish with the stock below key long-term moving averages and a negative MACD. These negatives are partially offset by a positive clinical-trial update and a relatively manageable leverage profile.

Positive Factors

Clinical validationPositive Phase 1/2 safety and tolerability results, together with measurable biological activity, support continued development of ENTR-601-45. Higher-dose cohorts and longer follow-up could clarify efficacy, giving the lead program a credible path to stronger clinical validation.

Negative Factors

Weak revenue performanceThe substantial quarterly revenue shortfall and declining TTM revenue indicate that the business has not yet established a dependable commercial or recurring revenue base. Continued reliance on clinical progress rather than growing operating revenue increases funding sensitivity and limits earnings visibility.

Entrada Therapeutics Inc (TRDA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $190.40M
Dividend Yield: ―
Average Volume (3M): 344.62K
Price to Earnings (P/E): -1.3
Beta (1Y): 0.95
Revenue Growth: -93.54%
EPS Growth: -53.55%
Country: US
Employees: 152
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Entrada Therapeutics Inc Business Overview & Revenue Model

Company Description

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV plat...

Entrada Therapeutics Inc Financial Statement Overview

Summary

Financials are pressured by a sharp swing from profitability in 2024 to very large operating/net losses in 2025 and TTM, alongside continued material cash burn (operating cash flow roughly -$129M to -$136M) and declining equity. The main offset is manageable leverage (low debt-to-equity), but current earnings quality and cash sustainability are weak.

Income Statement

28Negative

Balance Sheet

62Positive

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.98M	25.42M	210.78M	129.01M	0	0
Gross Profit	2.29M	21.32M	210.78M	129.01M	0	0
EBITDA	-162.33M	-138.73M	70.26M	14.90M	-90.09M	-50.04M
Net Income	-161.39M	-143.75M	65.63M	-6.68M	-94.62M	-51.16M
Balance Sheet
Total Assets	266.88M	377.38M	526.32M	469.19M	252.06M	305.83M
Cash, Cash Equivalents and Short-Term Investments	193.01M	295.70M	420.00M	351.97M	188.71M	291.06M
Total Debt	47.31M	50.93M	59.21M	68.23M	25.94M	0
Total Liabilities	68.56M	71.25M	97.64M	226.83M	39.50M	7.12M
Stockholders Equity	198.32M	306.13M	428.68M	242.36M	212.55M	298.72M
Cash Flow
Free Cash Flow	-136.33M	-129.55M	-44.72M	134.19M	-96.67M	-55.44M
Operating Cash Flow	-136.32M	-128.51M	-41.56M	139.80M	-93.79M	-50.86M
Investing Cash Flow	153.98M	116.81M	-27.80M	-138.40M	-148.65M	-4.58M
Financing Cash Flow	642.00K	887.00K	102.96M	21.04M	479.00K	307.46M

Entrada Therapeutics Inc Technical Analysis

Technical Analysis SentimentNeutral

Last Price4.89

Price Trends

50DMA5.80Negative

100DMA6.43Negative

200DMA8.61Negative

Market Momentum

MACD-0.27Negative

RSI47.66Neutral

STOCH66.10Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Neutral. The current price of 4.89 is above the 20-day moving average (MA) of 4.75, below the 50-day MA of 5.80, and below the 200-day MA of 8.61, indicating a neutral trend. The MACD of -0.27 indicates Negative momentum. The RSI at 47.66 is Neutral, neither overbought nor oversold. The STOCH value of 66.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TRDA.

Entrada Therapeutics Inc Risk Analysis

Entrada Therapeutics Inc disclosed 93 risk factors in its most recent earnings report. Entrada Therapeutics Inc reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.Our failure or perceived failure to achieve our corporate sustainability goals or maintain corporate sustainability practices that meet evolving stakeholder expectations could adversely affect us.Q1, 2026

Entrada Therapeutics Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TRDA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRRO	55Neutral	$202.45M	-1.63	-117.05%	―	-82.47%	3.73%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BNTC	49Neutral	$332.84M	-9.73	-28.41%	―	―	14.04%
TRDA	47Neutral	$191.45M	-1.27	-64.00%	―	-93.54%	-53.55%
PEPG	45Neutral	$171.07M	-1.65	-51.01%	―	―	56.00%
PRQR	42Neutral	$190.51M	-3.06	-68.44%	―	19.49%	-4.53%
VYGR	42Neutral	$116.06M	-1.07	-63.42%	―	-19.82%	19.88%

* Healthcare Sector Average

Performance Comparison

TRDA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TRDA	Entrada Therapeutics Inc	4.89	-2.37	-32.64%
PRQR	ProQR Therapeutics BV	1.35	-0.81	-37.50%
BNTC	Benitec Biopharma	9.54	-3.35	-25.99%
VYGR	Voyager Therapeutics Inc.	1.86	-2.39	-56.22%
KRRO	Korro Bio, Inc.	14.75	-17.87	-54.78%
PEPG	PepGen Inc.	2.47	-1.79	-42.02%

Entrada Therapeutics Inc Corporate Events

Business Operations and StrategyProduct-Related Announcements

Entrada Therapeutics reports positive ENTR-601-45 trial results

Positive

Oct 14, 2026

On October 14, 2026, Entrada Therapeutics reported positive topline results from Cohort 1 of its global Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 in ambulatory Duchenne muscular dystrophy patients amenable to exon 45 skipping. The initial multipl...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026

Entrada Therapeutics Inc AI Stock Analysis